Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 4/20 | 0.36 |
| ▸ | CES1 | P23141 | 4/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21857875 | 0.80 | FBP1 (0.39) | APLNRPKMMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29622932 | 0.80 | FBP1 (0.39) | APLNRPKMMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1343758 | 0.80 | APLNR (0.36) | APLNRCES2CES1PKMGPR139 | |
| SCHEMBL22922248 | 0.76 | APLNR (0.35) | APLNRCES2CES1PKMPDE2A | |
| SCHEMBL28002623 | 0.73 | CES2 (0.37) | CES2CES1PKMMAPTNPC1 | |
| SCHEMBL6858040 | 0.72 | APLNR (0.43) | APLNRCES2CES1PKMGPR139 | |
| SCHEMBL30848143 | 0.72 | APLNR (0.43) | APLNRCES2CES1PKMGPR139 | |
| SCHEMBL2478679 | 0.72 | APLNR (0.43) | APLNRCES2CES1PKMGPR139 | |
| SCHEMBL3708094 | 0.72 | APLNR (0.43) | APLNRCES2CES1PKMGPR139 | |
| SCHEMBL27554624 | 0.71 | APLNR (0.40) | APLNRCES2CES1PKMGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202970-A1 | PROCESS OF PREPARING 3-FLUORO-5(((1R,2AR)-3,3,4,4-TETRAFLUORO-1,2A-DIHYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)-OXY)BENZONITRILE | NIKANG THERAPEUTIC INC (US) | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202970-A1 | PROCESS OF PREPARING 3-FLUORO-5(((1R,2AR)-3,3,4,4-TETRAFLUORO-1,2A-DIHYDROXY-2,2A,3,4-TETRAHYDRO-1H-CYCLOPENTA[CD]INDEN-7-YL)-OXY)BENZONITRILE | CYP4B1, CYP1B1, CYP3A4 | APLNR 4360/4885CES2 1159/4885CES1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.